Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | CTSV | O60911 | 4/20 | 0.38 |
| ▸ | CTSL | P07711 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | PPIA | P62937 | 4/20 | 0.37 |
| ▸ | PPIF | P30405 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | MAX | P61244 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586707 | 1.00 | PTGES (0.42) | PTGESCTSVCTSLKMT2APPIA | |
| SCHEMBL3586703 | 1.00 | PTGES (0.42) | PTGESCTSVCTSLKMT2APPIA | |
| SCHEMBL3877870 | 0.92 | SMN1; SMN2 (0.40) | PTGESCTSVCTSLKMT2APPIA | |
| SCHEMBL3877875 | 0.92 | SMN1; SMN2 (0.40) | PTGESCTSVCTSLKMT2APPIA | |
| SCHEMBL3587958 | 0.87 | PPIA (0.41) | PTGESCTSVCTSLKMT2APPIA | |
| SCHEMBL30105376 | 0.78 | RAB9A (0.46) | PTGESCTSVCTSLKMT2AMAPT | |
| SCHEMBL1447461 | 0.77 | PTGES (0.40) | PTGESCTSVCTSLKMT2AMAPT | |
| SCHEMBL3593506 | 0.77 | CTSV (0.42) | PTGESCTSVCTSLKMT2APPIA | |
| SCHEMBL3593504 | 0.76 | NPC1 (0.45) | PTGESCTSVCTSLKMT2AMAPT | |
| SCHEMBL3593509 | 0.76 | NPC1 (0.45) | PTGESCTSVCTSLKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446012-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-09-20 | — | — | US | disclosed |
| EP-2027091-B1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL PORTELA & CA SA (PT) | 2016-01-06 | — | — | EP | disclosed |
| US-20140024682-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2014-01-23 | — | — | US | disclosed |
| US-8536203-B2 | Pharmaceutical compounds | BIAL-PORTELA & CA, S.A. (PT) | 2013-09-17 | — | — | US | disclosed |
| EP-2617713-A1 | New Pharmaceutical Compounds | BIAL - Portela & Ca., S.A. (PT) | 2013-07-24 | — | — | EP | disclosed |
| US-20100168113-A1 | Pharmaceutical Compounds | BIAL-PORTELA & CA., S.A. (PT) | 2010-07-01 | — | — | US | disclosed |
| EP-2027091-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - Portela & Ca., S.A. (PT) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007117165-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168113-A1 | Pharmaceutical Compounds | PMP22, CNR2, OPRL1 | PTGES 94/4885CTSV 2563/4885CTSL 2535/4885 |
| US-20140024682-A1 | PHARMACEUTICAL COMPOUNDS | PMP22, CNR2, OPRL1 | PTGES 94/4885CTSV 2563/4885CTSL 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.